Product Description
Febuxostat is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for hematological malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS). Febuxostat is also used to lower hyperuricemia in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol. The primary mechanism of action of febuxostat evaluated in trials was the inhibition of xanthine oxidase, evidenced by the increase in serum and urine xanthine concentrations, decrease in serum and urine uric acid levels, and lack of significant reduction in total purine synthesis.
